Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 19;7(11):101123.
doi: 10.1016/j.xkme.2025.101123. eCollection 2025 Nov.

Comparison of Acute Kidney Disease Staging by Estimated Glomerular Filtration Rate and by Serum Creatinine Ratio in Patients With Dialysis-requiring Acute Kidney Injury: A National Cohort Study From Taiwan

Affiliations

Comparison of Acute Kidney Disease Staging by Estimated Glomerular Filtration Rate and by Serum Creatinine Ratio in Patients With Dialysis-requiring Acute Kidney Injury: A National Cohort Study From Taiwan

Szu-Yu Pan et al. Kidney Med. .

Abstract

Rationale & objective: The comparative performance of 2 staging systems for acute kidney disease (AKD), based on estimated glomerular filtration rate (AKDeGFR) or serum creatinine ratio (AKDsCr), remains uncertain. Our objective is to assess the predictive ability of these staging systems concerning outcomes.

Study design: Population-based retrospective observational cohort study.

Setting & participants: In total, 40,849 hospitalized patients with acute kidney injury requiring dialysis between July 1, 2015 and June 30, 2022, in the Taiwan National Health Insurance Research Database.

Tests compared: AKD stages were defined according to the Acute Dialysis Quality Initiative 16 Workgroup (AKDsCr) and 2021 Kidney Disease: Improving Global Outcomes Consensus (AKDeGFR). Cox proportional hazard models were constructed to examine associations between AKD stages and outcomes.

Outcomes: Mortality and sustained kidney recovery.

Results: The AKDeGFR staging system predicted both outcomes better than the AKDsCr staging system. Hazard ratios and 95% confidence intervals for mortality across increasing AKDeGFR stages were 1.29 (1.19-1.41), 1.78 (1.65-1.92), 2.68 (2.49-2.87), 3.11 (2.84-3.42), and 6.34 (6.07-6.63). Conversely, within the AKDsCr staging system, hazard ratios and 95% confidence intervals for mortality across ascending stages were 0.84 (0.75-0.94), 0.90 (0.77-1.04), 0.93 (0.75-1.16), and 4.32 (4.18-4.47). Subgroup and sensitivity analyses yielded consistent results.

Limitations: Retrospective analysis based on a claims database.

Conclusions: We conclude that the AKDeGFR staging system performs better than the AKDsCr staging system in patients with acute kidney injury requiring dialysis regarding all-cause mortality and kidney recovery. Future investigations are warranted to evaluate the comparative efficacy in patients with acute kidney injury not requiring dialysis.

Keywords: Acute kidney disease; acute kidney injury; dialysis; mortality; renal recovery; staging.

Plain language summary

Whether an acute kidney disease (AKD) staging system by estimated glomerular filtration rate (AKDeGFR) or by serum creatinine ratio (AKDsCr) performs better is unclear. We compared these 2 staging systems for predicting outcomes in patients with acute kidney injury requiring dialysis in a population-based database. We found that the AKDeGFR staging system outperformed the AKDsCr staging system for predicting mortality and sustained kidney recovery. These results provide critical insights into the risk stratification of AKD patients. Validation in independent cohorts including patients with nondialysis-requiring acute kidney injury is warranted.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The associations between AKD stages and outcomes in the AKDeGFR and the AKDsCr staging systems. The adjusted hazard ratios for mortality (A) and sustained renal recovery (B) across AKD stages in the AKDeGFR staging system (upper portion) and the AKDsCr staging system (lower portion) were shown. AKD stage 0 served as the reference. Dots and error bars represented the point estimates and the 95% confidence intervals of the hazard ratios. The covariates adjusted for were listed in Supplementary Tables S3 and S4.
Figure 2
Figure 2
Subgroup analysis of mortality risk in the AKDeGFR staging systems. The adjusted hazard ratios and 95% confidence intervals of different AKDeGFR stages for mortality in the multivariable Cox proportional hazard model according to prespecified subgroups were shown. The adjusted hazard ratio and 95% confidence interval in the original 40,849 cohort were also shown. Dots and error bars represented the point estimates and the 95% confidence intervals of the hazard ratios. CKD was defined as a baseline eGFR < 60 mL/min/1.73 m2. Two types of P values for interaction were provided. An interaction product variable, combining the covariate and AKD stage, was added to the multivariable model to test for interaction. The overall P value (Poverall) was estimated by comparing the multivariable models with and without the interaction product variable using a likelihood-ratio test. The P value for interaction (Pint) at each AKD stage was determined by the significance of the interaction product variable in the model. P < 0.003 was marked with an asterisk (∗) and claimed as statistically significant based on the Bonferroni correction, considering 2 outcomes and 9 exposures. Abbreviations: CCI, Charlson comorbidity index; CKD, chronic kidney disease.
Figure 3
Figure 3
Subgroup analysis of mortality risk in the AKDsCr staging systems. The adjusted hazard ratios (represented by dots) and 95% confidence intervals (represented by error bars) for sustained renal recovery were displayed for the original cohort of 40,849 patients and in prespecified subgroups. The definitions of CKD, Pint, Poverall, and statistical significance were the same as those in Figure 2. Abbreviations: CCI, Charlson comorbidity index; CKD, chronic kidney disease.

References

    1. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2:1–138.
    1. Chawla L.S., Bellomo R., Bihorac A., et al. Acute Disease Quality Initiative Workgroup 16 Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13:241–257. - PubMed
    1. Lameire N.H., Levin A., Kellum J.A., et al. Conference Participants. Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2021;100:516–526. - PubMed
    1. Pan Szu-Yu, T-MH, Jiang Zheng-Hong, et al. Unveiling the enigma of acute kidney disease: predicting prognosis, exploring interventions, and embracing a multidisciplinary approach. Kidney Res Clin Pract. 2024;43(4):406–416. - PMC - PubMed
    1. Su C.C., Chen J.Y., Chen S.Y., et al. Outcomes associated with acute kidney disease: A systematic review and meta-analysis. EClinicalMedicine. 2023;55 - PMC - PubMed

LinkOut - more resources